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Abstract
While few dispute the existence of the metabolic syndrome (MetS) as a clustering of factors 
indicative of poor metabolic health, its utility above that of its individual components in the clinical 
care of individual patients is questioned. This is likely a consequence of the failure of clinicians and 
scientists to agree on a unifying mechanism to explain the MetS. Insulin resistance has most 
commonly been proposed for this role and is generally considered to be a root causative factor for 
not only MetS, but also for its associated conditions of non-alcoholic fatty liver disease (NAFLD), 
polycystic ovarian syndrome (PCOS), obesity-related type 2 diabetes (T2D) and atherosclerotic 
cardiovascular disease (ASCVD). An alternative view, for which evidence is mounting, is that 
hyper-responsiveness of islet -cells to a hostile environment, such as westernised lifestyle, is 
primary and that the resulting hyperinsulinaemia drives the other components of the MetS. 
Importantly, within this new conceptual framework, insulin resistance, while always a biomarker 
and state of poor metabolic health, is not considered to be harmful, but a protective adaptive 
response of critical tissues including the myocardium against insulin-induced metabolic stress. This 
major shift in how MetS can be considered, puts insulin hypersecretion into position as the unifying 
mechanism. If shown to be correct, this new conceptual framework has major implications for the 
future prevention and management of the MetS, including its associated conditions of NAFLD, 
PCOS, obesity-related T2D and ASCVD.
Keywords
Cardiovascular diseases, insulin hypersecretion, insulin-mediated metabolic stress, insulin 
resistance, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes
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Prof Gerald “Jerry” Reaven, in his 1988 American Diabetes Association Banting Lecture titled 
“Role of insulin resistance in human disease”, showed strong associations between insulin 
resistance, hyperinsulinaemia, glucose intolerance, hypertriglyceridaemia, reduced high density 
lipoprotein cholesterol and hypertension.1 He termed the clustering of these factors “syndrome X” 
and demonstrated links between this syndrome and increased risk of atherosclerotic cardiovascular 
disease (ASCVD).1 Syndrome X, renamed “metabolic syndrome” (MetS) has been expanded to 
include additional factors such as central or visceral adiposity, increased apolipoprotein B and small 
dense LDL particles (proatherogenic), elevated plasma fibrinogen and plasminogen activator 
inhibitor (PAI)-1 (prothrombotic), increased C-reactive protein and inflammatory cytokines 
(systemic inflammation) and microalbuminuria.2,3 It is generally accepted that the clustered 
components of the MetS, including insulin resistance, contribute to the pathogenesis of conditions 
such as non-alcoholic fatty liver disease (NAFLD), polycystic ovarian syndrome (PCOS), type 2 
diabetes (T2D) and ASCVD.2-5 MetS has also been associated with increased risk for chronic 
kidney disease, cognitive impairment, obstructive sleep apnoea and chronic respiratory diseases.6-9 
While the usefulness of a diagnosis of MetS over its individual components in predicting T2D and 
ASCVD has been questioned, MetS is now listed as a disease entity (E88.81) in the International 
Classification of Diseases-10 (ICD-10), avowing to the importance of Reaven’s contribution in 
bringing this clustering of factors involved in cardiometabolic diseases to the attention of clinicians 
and scientists.1,10
Insulin resistance: root cause of MetS and T2D or a protective adaptive response?
Ongoing controversy surrounding the MetS, in terms of its predictive value for particular diseases, 
is a consequence of the failure of metabolic scientists and clinicians to establish it as a precise 
condition or to provide a unifying mechanism to explain its clustering of factors, with insulin 
resistance and visceral adiposity being most commonly proposed.2,10 Reaven argued for insulin 
resistance as the unifying mechanism or primary causal factor and, supporting this view, the 
European Group for the Study of insulin Resistance proposed “insulin resistance syndrome” as an 
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alternate name for MetS.1,11 Furthermore, the mainstream understanding of pathogenesis of T2D is 
that it develops as a consequence of failure of pancreatic islet -cells to sustain the 
hyperinsulinaemia required to compensate for insulin resistance, giving insulin resistance a high 
level causative role.12,13 Thus, within the current conceptual framework, insulin resistance is 
considered to be “harmful” and the root cause of T2D and all the other conditions linked to the 
MetS; furthermore, it should be overcome at any cost. 
An alternate view gaining momentum is that insulin resistance has a role in protecting critical 
tissues of the body from metabolic injury in situations of chronic nutrient excess.14-17  Its presence 
within the MetS, while indicative and a biomarker of poor metabolic health, does not mean insulin 
resistance has a causative role. Furthermore, if insulin resistance does have an adaptive protective 
role, attempts to override it in patient treatment have the potential to cause harm. Thus, we believe a 
shift is needed in the conceptual fram work by which we understand insulin resistance and the 
aetiology of T2D and that this has implications on safe management of patients with MetS, T2D 
and related conditions.
Insulin sensitivity: adaptable to physiological demands
Physiological adaptability in insulin sensitivity is an important mechanism by which the body can 
regulate nutrient partitioning between tissues, necessitated by wide fluctuations in dietary intake 
and physical activity, and life events such rapid pubertal growth, pregnancy, illness and aging. For 
example, in response to short term overfeeding, a rapid fall in insulin sensitivity occurs which 
allows diversion of nutrients from skeletal muscle to adipose tissue for storage, potentially 
important moving between situations of feast and famine.18,19 Pregnancy necessitates diversion of 
nutrients to the developing fetus and insulin resistance in the mother is a mechanism by which this 
is achieved.20 Key to this discussion is the role of adaption in insulin sensitivity to a chronic nutrient 
oversupply, as occurs in westernized lifestyles. As discussed below, the development of insulin 
resistance in such situations could provide important protection to critical tissues such as the heart 
from nutrient overload and toxicity.14-17
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Insulin resistance: a protective mechanism against nutrient-induced intracellular metabolic 
stress
We previously proposed that in response to chronic over-nutrition, tissues normally responsive to 
insulin for glucose uptake, such as the heart and skeletal muscle, protect themselves from nutrient-
induced toxicity by becoming insulin resistant.14,15 Without this mechanism at times of nutrient 
surplus, or by overriding this protective insulin resistance with high dose insulin therapy, these 
tissues will be damaged by nutrient overload, a process we have termed “insulin-induced metabolic 
stress” (Figure 1).14,15
A failure to limit excess entry of glucose at times of concomitant high free fatty acid (FFA) 
availability will cause cell injury by the mechanisms of glucolipotoxicity.12 High FFA availability 
will inhibit glucose oxidation at the level of pyruvate dehydrogenase, such that a high glucose flux 
will be forced into pathways above this step, including glycogen synthesis, the polyol and 
hexosamine pathways, and the production of advanced glycation end product (AGE) precursors 
(Figure 1).21,22 Similarly, high glucose availability, via malonyl-CoA/AMPK metabolic sensing 
mechanisms, will inhibit FFA oxidation such that intracellular FFA metabolism will be pushed 
towards esterification and other processes causing intracellular steatosis and accumulation of 
complex lipids such as diacylglycerols, cholesterol esters,  and ceramides (Figure 1).23,24 An 
excessive mixed nutrient entry into cells will also overload the electron transfer chain resulting in 
mitochondrial dysfunction and increased reactive oxygen species (ROS) production.25,26 
Endoplasmic reticulum stress and activation of the inflammasome are also known consequences of 
excessive nutrient entry.23,27-29 The concept of “insulin-induced metabolic stress” has been 
discussed in more detail previously.15 
Islet -cell role in obesity and T2D: upstream or downstream of insulin resistance?
The predominant view is that islet -cell failure in obesity-related T2D is a consequence of it not 
being able to sustain high enough insulin secretion to compensate for insulin resistance, suggesting 
it is downstream and a victim of insulin resistance.12 However, increasing evidence from pre-
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clinical and clinical studies support an alternate possibility, at least in subsets of individuals at risk 
of T2D, that hyper-responsiveness of the islet -cell to a hostile environment (e.g. from a 
westernised lifestyle) drives hyperinsulinaemia, this being the culprit and upstream to excessive 
weight gain, insulin resistance, subsequent -cell failure and the development of T2D.30-33
There is considerable heterogeneity in islet -cell function in mouse strains with those that have a 
tendency for insulin hypersecretion (e.g. DBA/2 compared to the C57Bl/6 and 129T2 strains) being 
more prone to high fat diet induced weight gain and -cell failure.33,34 Furthermore, there are 
several examples by which suppression of insulin secretion through genetic manipulation can 
reduce high fat diet-induced obesity and insulin resistance. Islet -cell specific deletion of the 
adipose triglyceride lipase, through reducing the lipid amplification arm of fuel induced insulin 
secretion, protects mice from obesity, hyperinsulinaemia, insulin resistance and hyperglycaemia.35 
Additionally, through suppressing insulin secretion by knocking out three of the four insulin gene 
alleles (Ins1-/- ; Ins2+/- and Ins1-/- ;Ins2+/+), it has been shown that aging female mice have lower 
glycaemia, improved insulin sensitivity and an extended life span.36 The model less predictably 
altered insulin secretion in male mice.30 In the leptin deficient ob/ob mouse model of obesity, a 
similar genetic approach to lowering insulin secretion, while successfully being able to attenuate 
obesity, resulted in the development of diabetes, indicative of a need for compensatory 
hyperinsulinaemia for obesity related insulin resistance when a rare monogenic cause of obesity 
rather than hyperinsulinaemia is the primary cause of the excessive weight gain.37
Of relevance within human studies is the Da Qing Children Cohort Study which showed that fasting 
insulin at about age 5 years, after the adjustment for age, sex, birth weight, TV-viewing time and 
weight (or body mass index) at baseline, predicted weight gain from age 5 to 10 years.38 
Furthermore, higher insulin levels at 5 years of age were also predictive of higher levels of systolic 
blood pressure, fasting plasma glucose, insulin resistance as determined by the homeostasis model, 
and triglycerides at 10 years of age, all features of the MetS.38 The findings were similar to those in 
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a study of Pima Indian children.39 Additionally, adolescent girls with polycystic ovarian syndrome 
have been shown to have early onset insulin hypersecretion in association with insulin resistance.40
Pharmacological approaches to suppress insulin secretion in humans also support the view that 
hyperinsulinaemia may have more of a primary role in the MetS. In obese men, 6 months treatment 
of lifestyle change with either diazoxide (DZ) alone (inhibits insulin secretion by activating the 
ATP sensitive potassium channels), DZ with metformin (DZ+M), or placebo, showed that DZ (DZ 
and DZ+M groups combined) markedly reduced fasting insulin levels by 72% compared to only 
23% in the placebo group (P<0.001), and this was accompanied by greater improvements in body 
weight, LDL-cholesterol, HDL-cholesterol, triglyceride, systolic and diastolic blood pressure.41 
Similar findings were found when hyperinsulinaemia was suppressed by the somatostatin analogue 
octreotide-LAR in obese subjects, with evidence of responders and non-responders to this therapy.42 
Also of relevance, in subjects with T2D, short term DZ use is capable of restoring islet -cell 
function through -cell rest.43,44 
Thus, considerable evidence points to insulin hypersecretion as being at, or close to, the root cause 
of MetS and its related conditions, with insulin resistance being downsteam.  Focus on reducing 
insulin hypersecretion, at least early in the course of these conditions, is likely to have beneficial 
metabolic effects. 
Towards better stratification of diabetes: subset of severe insulin resistant and 
hyperinsulinaemic diabetes
Within a recently reported study of adult-onset diabetes from Scandinavia, 5 subgroups were 
identified: severe autoimmune diabetes (SAID); severe insulin-deficient diabetes (SIDD); severe 
insulin-resistant diabetes (SIRD); mild obesity-related diabetes (MOD); mild age-related diabetes 
(MARD).45 
The subgroup that seems most relevant to this discussion is SIRD, with the predominant 
characteristics being obesity, severe hyperinsulinaemia and insulin resistance. An alternative name 
for this subgroup could have been “severe hyperinsulinaemic diabetes”. Individuals within this 
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subgroup, in keeping with the concept of insulin-induced metabolic stress, were also more likely to 
develop diabetic nephropathy and have coronary events.45 Surprisingly, the age of diabetes onset in 
the SIRD group was relatively high, which may relate to the predominant Scandanavian ethnicity 
within the diabetes registries used.45 The SIRD subgroup characteristics of more severe 
hyperinsulinaemia and insulin resistance tend to be mirrored in young people presenting with 
obesity-related T2D, as was found in the Restoring Insulin Secretion (RISE) study and is also 
reported in various high risk indigenous groups.40,46,47 T2D in youth is also associated with a much 
higher risk of early-onset nephropathy and macrovascular disease.40 If in this subset of diabetes 
(SIRD), insulin hypersecretion rather than insulin resistance has the primary role, as remains to be 
determined, it will have major implications on the best approaches to prevention and treatment.
In the SIDD, MOD and MARD subgroups, insulin resistance is of lesser degree at the time of 
diabetes diagnosis, however, islet -cell failure must be involved in the pathogenesis. Whether mild 
suppression of insulin secretion in at least some of those at risk within these subgroups would 
prevent this -cell failure and T2D development is unknown. A precision medicine approach will 
most likely be required in which the correct approach to diabetes prevention and treatment will 
require detailed phenotypic and genotypic classification of individual patients within these 
subgroups.
A paradigm shift: new conceptual framework for considering insulin resistance and the MetS
If insulin resistance, while clearly being a biomarker of poor metabolic health, is also to be 
considered a defensive mechanism used by critical tissues against hyperinsulinaemia and nutrient 
overload, a complete revision of the conceptual framework within which hyperinsulinaemia, insulin 
resistance and the MetS are viewed, is needed (Figure 2). Such a revision is not trivial, as it has 
major implications for how MetS and its associated conditions, including T2D, PCOS, NAFLD and 
ASCVD, should be prevented and managed. Within this new framework and paradigm shift, 
hyperinsulinaemia has a more primary or causative role. In doing so, instead of the role of the islet 
-cell being one of “compensation” for insulin resistance, it becomes the primary driver, with 
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insulin hypersecretion and the resulting hyperinsulinaemia taking up position as the unifying 
mechanism. Thus, the development of new therapeutic approaches for MetS, and at least the SIRD 
subgroup of T2D, will need to move to prevention and/or suppression of the hypersecreting -cell 
(Figure 2). Approaches to lower glucose and other elevated nutrients in the blood of MetS and T2D 
patients through overriding the protective role of insulin resistance will be contraindicated, as we 
and others have previously advocated.
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14-17 While research into mechanisms of islet -cell failure and insulin resistance will continue to be 
important, more focus on the mechanisms driving insulin hypersecretion will be required, whether 
they be genetic or acquired, including those acquired early in life from epigenetic processes and/or  
consequent on islet -cell response to new environmental exposures.31 
Relevance to management of T2D
Optimisation of cellular nutrient status 
In managing disturbed metabolic homeostasis in T2D, the focus of clinicians is currently on 
normalising glucose and lipid parameters in the blood. Less thought is given to optimising 
intracellular metabolism, even though nutrient-induced tissue injury in obesity-related T2D is 
predominantly a consequence of excess entry of nutrients from the blood into cells. This is 
understandable, as measuring nutrient levels is much easier in blood (e.g. blood glucose, HbA1c, 
plasma triglycerides) than in cells. The corollary is that approaches to normalise glycaemia in 
obesity-related T2D that drive glucose and other nutrients into already nutrient overloaded cells, 
such as by high dose insulin therapy or sulphonylureas to override insulin resistance, or insulin 
sensitisers to reverse insulin resistance depending on mechanism of action, may unintentionally 
cause harm.15 According to this argument, alternative approaches to lowering glycaemia that 
nutrient off-load cells, such as intensive lifestyle measures, sodium glucose transporter 2 (SGLT2) 
inhibitors, glucagon-like peptide-1 receptor agonists or bariatric surgery, should be beneficial in the 
majority of patients with obesity-associated T2D (Figure 3A).15 
The alternate scenario of intracellular nutrient depletion in patients with hypoinsulinaemic diabetes 
is also important to consider, particularly, with the increasing occurrence of cases of euglycaemic 
ketoacidosis in patients treated with SGLT2 inhibitors.48 Avoidance of SGLT2 inhibitors and most 
often a shift to insulin therapy will be necessary in such patients (Figure 3B).
Thus, the approach to diabetes management should take into account some consideration of cellular 
nutrient status (Figure 3). For these reasons, new blood biomarkers of cellular nutrient or energy 
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status may also be of value in patient care and once discovered should be examined for clinical 
utility. 
In support of the proposition that glucose lowering approaches that work by driving glucose into 
tissues can be harmful in overweight and obese subjects with T2D and insulin resistance, we 
reviewed major T2D clinical trials and found that whenever intensive glucose lowering approaches 
were associated with weight gain of greater than 1.0 kg/year (ACCORD, Veterans Affairs Diabetes 
Trial (VADT), Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 
(DIGAMI 2)), cardiovascular and all-cause mortality increased, although only reaching statistical 
significance in ACCORD given the greater sample size.15 Furthermore, among adults with diabetes 
and stable ischaemic heart disease aged ≥75years, insulin provision therapy was associated with an 
increased risk for all-cause-mortality (hazard ratio 1.89, CI 1.1-3.2, p=0.020).49 
In support of the benefits of nutrient off-loading approaches are more recent clinical trials of new 
classes of glucose lowering agents, such as SGLT2 inhibitors (by promoting urinary glucose loss) 
and GLP-1 receptor agonists (by reducing weight through increased satiety), as well as bariatric 
surgery that have demonstrated reductions in major adverse cardiovascular and renal outcomes in 
high-risk T2D patients.50-52 The recent consensus statement of the ADA and EASD on the 
management of hyperglycaemia in T2D has taken the results of these major clinical trials in their 
recommendations.53 
Prevention of insulin hypersecretion
The nutrient off-loading approaches to glucose-lowering available in the management of T2D, 
including intensive lifestyle change, SGLT-2 inhibitors, GLP-1 receptor antagonists, -glucosidase 
inhibitors, bariatric surgery, will all reduce insulin hypersecretion. However, often these therapies 
are started once T2D is established and failure of islet -cells has already commenced. Optimal 
approaches for reversal of severe hyperinsulinaemia in patients prior to development T2D or early 
in its course, in particular in younger individuals, when lifestyle measures are generally 
unsuccessful, are not known. Of note, bariatric surgery has been shown to be effective in reversing 
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hyperinsulinaemia and MetS in obese adolescents.54  In the RISE study, neither 3 months of insulin 
glargine followed by 9 months of metformin, nor 12 months of metformin alone, slowed the 
progressive deterioration of β-cell function in young people with early T2D, suggesting different 
approaches are required.55 The development of specific islet -cell therapies to limit insulin 
hypersecretion in high-risk individuals with MetS related conditions and obesity-related pre-
diabetes and early T2D should be pursued. 
Conclusion
The part played by Jerry Reaven in linking the dots between the various components of the MetS 
and the relevance of MetS to ASCVD, NAFLD, PCOS and T2D has been enormously important. 
The search for the unifying mechanism has been contentious. Here, we make a case for putting 
“insulin hypersecretion” into this role, while considering insulin resistance as a protective 
downstream response. This necessitates a complete revision of the conceptual framework within 
which we view insulin resistance and the pathophysiology of the MetS and obesity-associated T2D, 
which if confirmed, has major implications for the prevention and management of these metabolic 
conditions.
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Figure Legends
Figure 1.  Model illustrating the molecular basis of insulin-induced metabolic stress in obese 
insulin resistant and poorly controlled type 2 diabetes patients.   Depicted is a cell in which: (A) 
insulin resistance (IR) protects from nutrient overload and metabolic stress by limiting glucose flux 
into the cell at times when both glucose and free fatty acids (FFA) are elevated in blood, and; (B) 
the IR protection is overridden by a high dose of exogenous insulin therapy which promotes excess 
glucose uptake and both glucotoxicity and lipotoxicity. High FFA availability inhibits glucose 
oxidation at the level of pyruvate dehydrogenase (PDH), such that a high glucose flux promoted by 
high levels of insulin will be forced into glucotoxic pathways above this step, including the polyol 
and hexosamine pathways, as well as the production of advanced glycation endproduct (AGE) 
precursors. Furthermore, high glucose availability promotes build-up of cytosolic malonyl-CoA 
which will inhibit carnitine palmitoyltransferase 1 (CPT1) and the transfer of long-chain acyl-CoAs 
(LC-AcylCoA) into mitochondria for -oxidation. This will result in a push of intracellular FFA 
metabolism towards synthesis of complex lipids, such as diacylglycerols, cholesterol esters and 
ceramides, and steatosis causing lipotoxicity.  Excess glucose supply to the mitochondria in the 
presence of high FFA supply will also promote reactive oxygen species (ROS) production and 
oxidative damage. CD36, free fatty acid transporter; GLUT4, facilitative glucose transporter 4; Ins-
R, insulin receptor.
Figure 2.   A new conceptual framework for considering insulin resistance and the metabolic 
syndrome (MetS) and its associated disorders.   The key changes in this conceptual framework 
are the roles of hyperinsulinaemia and insulin resistance in the MetS. Islet -cell hyper-
responsiveness to adverse environmental factors in genetically or epigenetically predisposed 
individuals results in hyperinsulinaemia and this is the primary driver of the MetS. Insulin 
resistance provides protection for critical tissues against insulin-induced metabolic stress and, while 
being a biomarker of metabolic ill health, is not a driver of pathogenesis. The characteristic features 
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of MetS are driven by hyperinsulinaemia. The MetS related disease entities, type 2 diabetes (T2D), 
cardiovascular diseases (CVD), non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis 
(NAFLD/NASH) and polycystic ovarian syndrome (PCOS) are a downstream consequence of 
hyperinsulinemia and the MetS.
Figure 3.  Optimisation of cellular nutrient status in patients with hyper- or hypo- 
insulinaemic type 2 diabetes: importance of the approach to glucose lowering.   (A) In 
untreated type 2 diabetes (T2D) with hyperinsulinaemic diabetes, insulin resistance (IR) protects 
insulin-responsive cells such as cardiomyocytes and skeletal muscle cells from nutrient overload; 
cells such as endothelial cells that are non-responsive to insulin with respect to glucose uptake, 
however, are not protected and are injured by glucotoxicity contributing to diabetes complications 
(left panel). Glucose lowering approaches that override the physiological IR to force glucose into 
insulin-responsive tissues (e.g. by high-dose insulin therapy) may reduce glucotoxicty in some 
tissues, but at the cost of nutrient-induced injury to the insulin-responsive tissues (e.g. causing a 
metabolic cardiomyopathy) (centre panel). Glucose lowering approaches that off-load glucose from 
cells of critical body tissues, by either reducing glucose entry into the blood (e.g. intensive lifestyle, 
-glucosidase inhibitors, bariatric surgery) or glucose clearance from the blood via non-toxic routes 
(e.g. SGLT2 inhibitors to promote urinary glucose loss, exercise, activation of brown adipose 
tissue), will reduce nutrient-induced tissue injury in all cell types (right panel).   (B) In untreated 
hypoinsulinaemic T2D, a starvation response to insulin deprivation occurs in which free fatty acid 
(FFA) release from adipose tissue is increased and hepatic ketone body production is increased; 
cardiomyocytes and skeletal muscle cells are starved of glucose and switch to use FFA and ketone 
body for energy; cells such as endothelial cells are not protected from hyperglycaemia (left panel). 
In this circumstance insulin therapy will prevent the starvation response and normalise cellular 
nutrient status in insulin-responsive tissues and prevent glucotoxicity in endothelial cells (centre 
panel). Glucose lowering approaches that off-load glucose from cells (e.g. by very low 
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carbohydrate diets or fasting for surgery) together with glucose clearance from the blood (e.g. 
SGLT2 inhibitors) will exacerbate the starvation response in hypoinsulinaemic T2D and induce 
euglycaemic ketoacidosis (right panel). Healthy cells shown in green; unhealthy nutrient-
overloaded cells shown in red; unhealthy nutrient-deprived cells shown in blue.
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